Anastasiia A. Ageeva
Anastasiia A. Ageeva has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alfiya Oskarovna Iusupova
IM. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
1 shared publication - Anastasiya Shchendrygina
Sechenov University
1 shared publication - Anna S. Malanova
P.Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre
1 shared publication - E. V. Privalova
First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, Russian Federation
1 shared publication - E. Yu. Salakheeva
Sechenov First Moscow State Medical University
1 shared publication - Guzal R. Abuzarova
P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Centre for Radiology of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
1 shared publication
Latest Publications
- 25 December 2024
- Published by ECO-Vector LLC in Regional Anesthesia and Acute Pain Management
- Vol. 18 (4) , 356-372
Experience with an opioid peptide (tyrosyl-D-arginyl-phenylalanyl-glycine amide) in oncology: a comparative randomized clinical study
Background: The application of tyrosyl-D-arginyl-phenylalanyl-glycine amide, a highly specific μ1-opioid receptor agonist, represents a promising approach for managing acute postoperative pain. Aim: To evaluate the efficacy and safety of tyrosyl-D-arginyl-phenylalanyl-glycine amide in oncology patients, depending on the type of anesthesia used for various surgical interventions. Materials and methods: A comparative randomized clinical study included 80 patients aged 29–86 years [median age (Me) 66 years, interquartile range (Q1; Q3) 59–71 years], of whom 46 (57.5%) were men and 34 (42.5%) were women, classified as American Society of Anesthesiologists (ASA) physical status I–III. These patients underwent planned surgical treatment for oncological diseases. Patients received either multimodal combined general anesthesia with mechanical ventilation in the control group (Group K, n=40) or combined anesthesia (general+epidural/intercostal block for thoracic surgeries) in the comparison group (Group C, n=40). All patients were administered a standardized postoperative systemic analgesia protocol based on tyrosyl-D-arginyl-phenylalanyl-glycine amide at a dose of 4 mg 3 times per day. The first dose was administered when pain intensity exceeded 3 points at rest and 4 points during movement on the Numeric Rating Scale (NRS). Pain intensity was assessed at rest and during movement at predetermined time points: 15, 30, 45, 60, 120, and 240 minutes after the first dose. Results: Baseline pain intensity at rest (NRS) was higher in Group K compared to Group C [Me=6, (Q1; Q3)=(5; 5) and (5; 6), respectively; p=0.038]. While initial pain intensity during movement was similar between groups (Me=7 points), the interquartile range was greater in Group K [(Q1; Q3) = (6; 8)] compared to Group C [(6; 7); p=0.045]. Lower pain scores were observed in Group C at 45 and 60 minutes at rest (p=0.005 and p=0.008, respectively) and at 30 minutes during movement (p=0.036). Conclusion: The combination of tyrosyl-D-arginyl-phenylalanyl-glycine amide with regional perioperative blocks is an optimal method for managing acute pain in the early postoperative period for patients undergoing complex and traumatic oncological surgeries.
- 25 December 2024
- Published by ECO-Vector LLC in Regional Anesthesia and Acute Pain Management
- Vol. 18 (4) , 356-372
Experience with an opioid peptide (tyrosyl-D-arginyl-phenylalanyl-glycine amide) in oncology: a comparative randomized clinical study
Background: The application of tyrosyl-D-arginyl-phenylalanyl-glycine amide, a highly specific μ1-opioid receptor agonist, represents a promising approach for managing acute postoperative pain. Aim: To evaluate the efficacy and safety of tyrosyl-D-arginyl-phenylalanyl-glycine amide in oncology patients, depending on the type of anesthesia used for various surgical interventions. Materials and methods: A comparative randomized clinical study included 80 patients aged 29–86 years [median age (Me) 66 years, interquartile range (Q1; Q3) 59–71 years], of whom 46 (57.5%) were men and 34 (42.5%) were women, classified as American Society of Anesthesiologists (ASA) physical status I–III. These patients underwent planned surgical treatment for oncological diseases. Patients received either multimodal combined general anesthesia with mechanical ventilation in the control group (Group K, n=40) or combined anesthesia (general+epidural/intercostal block for thoracic surgeries) in the comparison group (Group C, n=40). All patients were administered a standardized postoperative systemic analgesia protocol based on tyrosyl-D-arginyl-phenylalanyl-glycine amide at a dose of 4 mg 3 times per day. The first dose was administered when pain intensity exceeded 3 points at rest and 4 points during movement on the Numeric Rating Scale (NRS). Pain intensity was assessed at rest and during movement at predetermined time points: 15, 30, 45, 60, 120, and 240 minutes after the first dose. Results: Baseline pain intensity at rest (NRS) was higher in Group K compared to Group C [Me=6, (Q1; Q3)=(5; 5) and (5; 6), respectively; p=0.038]. While initial pain intensity during movement was similar between groups (Me=7 points), the interquartile range was greater in Group K [(Q1; Q3) = (6; 8)] compared to Group C [(6; 7); p=0.045]. Lower pain scores were observed in Group C at 45 and 60 minutes at rest (p=0.005 and p=0.008, respectively) and at 30 minutes during movement (p=0.036). Conclusion: The combination of tyrosyl-D-arginyl-phenylalanyl-glycine amide with regional perioperative blocks is an optimal method for managing acute pain in the early postoperative period for patients undergoing complex and traumatic oncological surgeries.
- Open Access
- 13 July 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (3) , 476-483
Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is heterogeneous in many ways, ethologically and phenotypically. The underlying mechanisms of the syndrome are not clear. Recently, it has been shown that the diagnostic criteria for HFpEF lacks sensitivity and specificity. Novel treatment approaches, which were developed based on current HFpEF pathophysiological concepts, did not show either clinical or prognostic benefit for patients. Therefore, there is an urgent need to revise current diagnostic approaches and to further investigate the underlying mechanisms. Recently, two novel diagnostic score systems were proposed: H2PEF and HFA-PEFF. Recently, a number of phase II and III randomized control trials have been completed. Here, the authors discuss the potential novel diagnostic approaches to HFpEF and treatment perspectives.
- 13 July 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (3) , 476-483
Open AccessHeart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is heterogeneous in many ways, ethologically and phenotypically. The underlying mechanisms of the syndrome are not clear. Recently, it has been shown that the diagnostic criteria for HFpEF lacks sensitivity and specificity. Novel treatment approaches, which were developed based on current HFpEF pathophysiological concepts, did not show either clinical or prognostic benefit for patients. Therefore, there is an urgent need to revise current diagnostic approaches and to further investigate the underlying mechanisms. Recently, two novel diagnostic score systems were proposed: H2PEF and HFA-PEFF. Recently, a number of phase II and III randomized control trials have been completed. Here, the authors discuss the potential novel diagnostic approaches to HFpEF and treatment perspectives.